초대의 글 일정표 프로그램 사전등록 초록접수 Special Lectures 호텔및교통 행사장안내
 
Satellite symposium 1 May. 10 (17:00~18:00)
| 좌장: 김선우
Sponsored by MSD
이병완
(연세의대)
Clinical experience with sitagliptin in Korean subjects with type2 diabetes
  
Satellite symposium 2 May. 10 (17:00~18:00)
| 좌장: 이형우
Sponsored by LG
이은정
(성균관의대 내과)
New clinical experience of gemigliptin
  
Breakfast symposium 1 May. 11 (07:30~08:30)
| 좌장: 강성구
Sponsored by 릴리
박석원
(차의과학대 내과)
What is the optimal insulin treatment when the patient is not adequately controlled with basal insulin?
  
Breakfast symposium 2 May. 11 (07:30~08:30)
| 좌장: 안유배
Sponsored by 사노피
김대중
(아주의대 내과)
Can we reduce CV complication by targeting normal glucose levels?
  
Breakfast symposium 3 May. 12 (07:30~08:30)
| 좌장: 이현철
Sponsored by 베링거인겔하임
최성희
(서울의대 내과)
Why do we need another the DPP-4 inhibitors?
  
Breakfast symposium 4 May. 12 (07:30~08:30)
| 좌장: 이광우
Sponsored by 노바티스
오태근
(충북의대 내과)
Comparison of vildagliptin-metformin and glimepiride-metformin treatments
in type 2 diabetic patients
  
Luncheon symposium 1 May. 11 (13:00~14:30)
| 좌장: 최동섭
Sponsored by 애보트
홍은경
(한림의대 내과)
Optimizing diabetic dyslipidemia beyond traditional risk factors:
is there a microvascular benefit?
  
Luncheon symposium 2 May. 11 (13:00~14:30)
| 좌장: 최영길
Sponsored by 아스트라제네카
박정현
(인제의대 내과)
What are the advantages of ONGLYZA(saxagliptin) for the treatment of
type 2 diabetes mellitus?
  
Luncheon symposium 3 May. 11 (13:00~14:30)
| 좌장: 조정구
Sponsored by 중외
서지아
(고려의대)
The new reliable options to treat dyslipidemia with diabetes mellitus
  
Luncheon symposium 4 May. 11 (13:00~14:30)
| 좌장: 박성우
Sponsored by 다케다
박철영
(성균관의대 내과)
Type 2 diabetes and cardiovascular risk: a multifactorial approach
  
Luncheon symposium 5 May. 12 (12:10~13:30)
| 좌장: 김영건
Sponsored by 한독
전성완
(순천향의대 내과)
Management of diabetic peripheral neuropathy
  
Luncheon symposium 6 May. 12 (12:10~13:30)
| 좌장: 궁성수
Sponsored by 노보노디스크
유순집
(가톨릭의대)
Insulin treatment strategies by new clinical trials
  
Luncheon symposium 7 May. 12 (12:10~13:30)
| 좌장: 허갑범
Sponsored by 대웅
조영민
(서울의대 내과)
Efficacy and safety of sitagliptin in various clinical settings of type 2 diabetes